Adults with moderate to severe Crohn’s disease can now begin Skyrizi treatment at home. The FDA has expanded its approval of risankizumab, made by AbbVie, to include a subcutaneous induction regimen delivered through an on-body injector pack. That is a practical change for patients who until now had to start in a clinic.
What changed
The drug won approval for this patient group in 2022, but the opening phase was given through a vein, followed by injections under the skin for maintenance. The new approval, announced in a manufacturer release, lets people skip the infusion and start from home. Roopal Thakkar, AbbVie’s chief scientific officer, said it builds on the drug’s efficacy while giving patients and physicians “greater flexibility in how treatment is initiated.”
Risankizumab is a humanized monoclonal antibody that targets interleukin 23A. It attaches to the IL-23 messenger protein, which helps drive inflammation, and blocks it from interacting with immune cells. Less pro-inflammatory activity means calmer tissue in the skin, joints and gut. It is also approved for plaque psoriasis, psoriatic arthritis and ulcerative colitis, and regulators in the European Union, Canada and Japan have cleared it.
The AFFIRM trial
The approval rests on the phase 3 AFFIRM trial of 289 adults with moderate to severe Crohn’s disease, each diagnosed at least three months earlier. Patients were randomly assigned two to one. Those on the drug received 720 mg under the skin at the start and again at weeks 2, 5 and 8 (191 patients), while the placebo group numbered 98.
At week 12, 55% of patients on risankizumab reached clinical remission, against 29.6% on placebo. Endoscopic response was 44% against 14.3%. The gap was widest among people who had never had an advanced therapy: 73.1% in remission versus 27.3%, with endoscopic response of 61.2% versus 15.2%. For those who had not responded well to, or could not tolerate, other biologics, remission was 45.2% versus 30.8%, and endoscopic response 34.7% versus 13.8%.
Millie D. Long, the trial’s lead investigator at the University of North Carolina School of Medicine, has said this class of medicines, the IL-23 p19 agents, seem “incredibly safe for advanced therapies and highly effective.”
Side effects and timing
The most common adverse events are upper respiratory infections, headache, joint and abdominal pain, injection-site reactions, anemia, fever, back pain, urinary tract infection and rash. Redness and pain at the injection site are uncommon, at about 0.8% of cases.
Skyrizi starts reducing inflammation after the first dose, but relief can take up to 24 weeks. The half-life in Crohn’s disease is about 21 days, and a drug typically needs four to five half-lives to clear the body. If there is no improvement in 12 to 24 weeks, some patients may have developed neutralizing antibodies, and previous biologic use can also lower the effect. Not everyone responds on the same timeline.
The encouraging part is that the results held up in people who had already tried other biologics. Patients should talk to their doctor about whether home induction suits their history, and about what to do if relief is slow.
Sources
- FDA approves subcutaneous induction regimen of Skyrizi for Crohn’s disease
- Risankizumab
- Skyrizi: How soon do you experience symptom relief?
Photo: Nappy / Unsplash (Unsplash License)





